Overall verdict
Neutral
5.8/10
1-year performance
+98.58%
Score breakdown
Up 98.6% over 1 year, 83% of the 52-week range.
Strongest: Valuation 9.4/10. Weakest: Profitability 2.8/10.
21 analysts, target +0.1% vs the price.
Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans.
This segment also provides healthcare products and services. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual and commercial group.
The Other segment operates clinical healthcare and pharmacies, as well as offers vision and dental, behavioral health, and centralized services. It provides services through primary and specialty care physicians, hospitals, behavioral health practitioners, and ancillary providers. The company was founded in 1984 and is headquartered in Saint Louis, Missouri.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nyse
United States
CEO
Sarah London
Founded
1984
Employees
61 100
Revenue / employee
3.2M USD
Next earnings
February 2, 2027 (estimated)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC2.85%
- Bank of New York Mellon Corp0.51%
- FMR LLC0.40%
- Rest of the register96.24%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
78.08 USD
52-week low
31.63 USD
1-year performance
98.58%
Rising
Year-to-date performance
69.89%
Rising
Drawdown
-10.40%
Mild pullback
Position in the 52-week range
83% of range
Against the world ETF
Over 25 years, from December 2001 to October 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned much more, but shaking 2.8 times harder: once that risk is counted, it did about as well as the ETF.
$10,000 placed at the end of December 2001 are worth today
| Centene | $374,212 |
| World ETF | $74,839 |
| S&P 500 | $103,358 |
| Risk-free placement | $15,365 |
The risk
- Shaking:the share moves 2.8 times as much as the world ETF.
- Worst fall:-74Â % between August 2022 and August 2025. $10,000 placed at the top fell to $2,593. The world ETF, at worst: -53Â %. The share has not returned to its high yet.
Centene earned 5 times as much as the world ETF since 2001
Value of $10,000 placed at the end of December 2001, dividends reinvested, in dollars
- Centene: $374,212
- World ETF: $74,839
- S&P 500: $103,358
- Risk-free placement: $15,365
Based on past performance. This is not a recommendation.
Range: 68.80 USD - 75.93 USD (3 methods agree)
The price implies growth of -5.94% per year; the company grows at 11.88%.
Gross margin 7.9%, net margin 0.7%, ROIC 3.8%, ROE 6.8%.
Net margin
0.72%
Low
Sector 1.68%|S&P 13.40%
Gross margin
7.91%
Low
Return on equity (ROE)
6.77%
Low
Sector 10.99%|S&P 17.06%
Return on invested capital (ROIC)
3.83%
Low
Free cash flow margin (FCF)
1.93%
Low
Profit-to-cash conversion (FCF conversion)
2.70x
High
Margin stability
2.2 pts
Steady
Revenue to net income
Growth
3.6/10Revenue up 1.9% over 1 year, 11.9% a year over 5.
Revenue (trailing 12 months)
204Md USD
Revenue growth (1y)
1.93%
Moderate
Revenue growth (3y)
34.75%
Solid
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
8.14%
Sharply revised up
Valuation
9.4/10P/E 24.0x, forward P/E 17.5x, EV/EBITDA 14.1x, PEG 0.24.
P/E (TTM)
24.0x
Fair
Sector 35.3x|S&P 23.6x
Forward P/E
17.5x
Cheap
EV / EBITDA
14.1x
Fair
Sector 18.5x|S&P 15.5x
PEG
0.24
Growth unpriced
Sector -0.20|S&P 0.91
Fair value (reverse DCF)
72.37 USD
Fairly priced
Market cap
34.6Md USD
Financial strength
8.1/10Cash covers 133.2% of the debt, net debt/EBITDA -1.4x.
Net debt / EBITDA
-1.4x
Net cash
Gearing (net debt / equity)
-23.12%
Net cash
Cash
20.7Md USD
Cash / market cap
59.77%
Very solid
Cash / total debt
133.19%
Net cash
Interest coverage
1.6x
Stretched
Net debt
-5.2Md USD
Equity
22.3Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 70.19 USD
- MM2069.72
- MM5066.85
- MM20056.21
- RSI 1453.2
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+4.93%
200-day average slope, 3 months
+17.62%
50-day average slope, 1 month
+2.84%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
3.63 % per day
Volatility change
+49.90%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 4.00 (8) | 5.28 (20) | 200 021 (14) | 3 147 (5) | 1 917 (9) |
| 2027 | 4.24 (8) | 5.55 (21) | 195 322 (15) | 3 322 (5) | 2 074 (9) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 4, 2026.
Same sub-industry: 10 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PGNY | 7.2 | 7.5 | 2.7Md USD | 33.5x | 6.8 % | 8.9 % | 17.8 % | -3.1x | 6.7 % | 53.4 % | ||
| 2 | HQY | 7.0 | 6.8 | 8.5Md USD | 37.2x | 17.4 % | 7.6 % | 7.7 % | 1.4x | 5.7 % | 3.4 % | ||
| 3 | ELV | 6.8 | 6.7 | 92.8Md USD | 18.3x | 2.5 % | 1.4 % | 6.8 % | 3.0x | 7.0 % | 40.0 % | ||
| 4 | UNH | 6.8 | 6.7 | 361Md USD | 23.0x | 3.5 % | -0.4 % | 9.5 % | 1.8x | 6.3 % | 24.6 % | ||
| 5 | SAUD3 | 6.4 | 5.9 | 8.4Md USD | 16.8x | 10.6 % | 1213.1 % | 10.4 % | -0.3x | 1.5 % | 36.5 % | ||
| 6 | CNC | 5.8 | 5.8 | 34.6Md USD | 24.0x | 0.7 % | 1.9 % | 3.8 % | -1.4x | 11.4 % | 98.6 % | ||
| 7 | HUM | 4.9 | 3.5 | 53.6Md USD | 43.4x | 0.8 % | 26.1 % | 4.1 % | -2.2x | 5.9 % | 86.0 % | ||
| 8 | MOH | 4.7 | 2.8 | 10.9Md USD | Not meaningful (loss) | -0.1 % | -3.4 % | -0.6 % | -22.1x | 2.2 % | 47.1 % | ||
| 9 | CLOV | 4.3 | 1.9 | 2.6Md USD | 263.0x | 0.5 % | 52.9 % | — | — | — | 91.2 % |
